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ABSTRACT
Tumor suppressor function can be modulated by subtle variation of expression 
levels, proper cellular compartmentalization and post-translational modifications, such 
as phosphorylation, acetylation and sumoylation. The non-genomic loss of function of 
tumor suppressors offers a challenging therapeutic opportunity. The reactivation of 
a tumor suppressor could indeed promote selective apoptosis of cancer cells without 
affecting normal cells. The identification of mechanisms that affect tumor suppressor 
functions is therefore essential. In this work, we show that BCR-ABL promotes the 
accumulation of the NFKBIA gene product, IκBα, in the cytosol through physical 
interaction and stabilization of the protein. Furthermore, BCR-ABL/IκBα complex acts 
as a scaffold protein favoring p53 nuclear exclusion. We therefore identify a novel 
BCR-ABL/IκBα/p53 network, whereby BCR-ABL functionally inactivates a key tumor 
suppressor.
INTRODUCTION
The involvement of tumor suppressors in cancer 
pathogenesis has been extensively revised over the last 
years. Originally, Knudson proposed that tumor suppressors 
play a role in tumorigenesis when both alleles are 
genetically impaired, one through point mutation and one 
through deletion [1]. Several data collected in non hereditary 
tumors and in murine models have clearly demonstrated 
that tumor suppressors’ involvement in cancer is a much 
more complex process [2]. In particular, tumor suppressor 
function can be modulated by subtle variation in protein 
expression levels, proper cellular compartmentalization 
and post-translational modifications of the protein, such 
as phosphorylation, acetylation and sumoylation [3, 4]. 
Chronic Myeloid Leukemia is a myeloproliferative disorder 
driven by the translocation t(9;22) which codes for the 
chimeric protein BCR-ABL [5–10]. Chronic Myeloid 
Leukemia has always been considered as an unique disease 
because it was referred as a ‘single hit’ cancer [11]. This 
interpretation is supported by the observation that BCR-
ABL alone is sufficient to induce the rapid onset of a 
leukemic phenotype in several murine models, without the 
need of additional genetic lesions [12]. Furthermore, no 
tumor suppressors have been reported mutated or deleted 
in the chronic phase of the disease, strongly supporting this 
unique biological feature of CML pathogenesis compared to 
other cancers. The revised model of tumor suppressor role in 
cancer suggests that BCR-ABL-mediated leukemogenesis 
could be associated with functional non genomic loss of 
tumor suppressors [2]. In this respect, PP2A and PTEN 
have already been described as BCR-ABL inhibited tumor 
suppressors [13–18]. Here, we demonstrate that BCR-ABL 
promotes the formation of a ternary complex with IκBα and 




While investigating the cellular compart mentalization 
of IκBα in CML formalin-fixed paraffin-embedded speci-
mens, we observed that IκBα was highly expressed 
and predominantly retained into the cytosol of myeloid 
progenitor cells when compared to normal bone marrow 
cells (Figure 1A). Interestingly, erythroid precursors do 
not express IκBα protein (Figure 1A). Similarly, IκBα 
immunofluorescence on CML primary cells showed that IκBα 
is expressed predominantly in the cytoplasm (Figure 1B). 
To evaluate whether IκBα cellular compartmentalization is 
regulated by BCR-ABL, we expressed BCR-ABL and myc-
tag-IκBα in HeLa cells. These cells were chosen because the 
large amount of cytoplasm allows to easily study cellular 
compartmentalization. As shown in Figure 1C, exogenous 
IκBα maintains a diffuse cellular compartmentalization in 
parental cell line, while expression of BCR-ABL promotes 
its nuclear exclusion. Notably, BCR-ABL and IκBα appeared 
also to co-localize (Figure 1C).
To better evaluate IκBα localization in CML cell 
lines, IκBα immunofluorescence was performed in the 
CML cell lines BV173 and K562 and in the Ba/F3 p210 
BCR-ABL cells [19]. As shown in Figure 1D, IκBα is 
mostly expressed in the cytosol of the BV173 and K562 
cell lines. Parental Ba/F3cells expressed IκBα both in the 
nucleus and in the cytosol, while Ba/F3 p210 BCR-ABL 
are characterized by IκBα nuclear exclusion (Figure 1D). 
Similar results were observed in the BCR-ABL-32D cell 
line (data not shown). Notably, imatinib treatment does not 
significantly revert IκBα cellular localization (Figure 1D).
The observation that BCR-ABL and IκBα co-localized 
in transfected HeLa cells (Figure 1C) suggests that BCR-
ABL could interact with IκBα. To test this hypothesis, 
HEK293T cells, upon transfection with BCR-ABL and IκBα 
vectors, were lysed and immunoprecipitation with myc-tag 
antibody was performed. As shown in Figure 2A, myc-
tag-IκBα interacts with BCR-ABL. To map the BCR-ABL 
region that interacts with IκBα, we transiently transfected 
a BCR expressing vector together with myc-tag-IκBα in 
the HEK293T cell line. As shown in Figure 2A, BCR-ABL 
physically interacts with IκBα through the BCR portion of 
the chimeric protein. Notably, in the CML BV173 cell line, 
endogenous BCR-ABL interacts with endogenous IκBα 
(Figure 2B). Due to the intrinsic nature of BCR-ABL as 
a tyrosine kinase, we next sought to investigate whether 
BCR-ABL promotes IκBα tyrosine phosphorylation. To 
this aim, we performed a kinase assay with purified IκBα 
protein. As shown in Figure 2C, IκBα is not phosphorylated 
by purified ABL in vitro. Although BCR-ABL does not 
directly phosphorylate IκBα, we next explored whether 
BCR-ABL could indirectly tyrosine phosphorylate IκBα 
in vivo. We performed immunoprecipitation of myc-tag-IκBα 
in BCR-ABL positive cells, and we assessed the phospho-
tyrosine status of IκBα by western immunoblot. IκBα does 
not appear to be phosphorylated in vivo (data not shown). 
This observation was also observed in the BV173 cell line, 
where immunoprecipitated IκBα does not hybridize with anti-
phosphotyrosine antibody (Figure 2B). All together these data 
suggest that IκBα behaves as a scaffold protein in BCR-ABL 
signaling. Next, we investigated if BCR-ABL regulates IκBα 
expression and stability. To evaluate IκBα mRNA expression 
levels, we performed qRT-PCR in BCR-ABL cell lines and 
primary CML cells. As shown in Figure 2D, there were no 
statistically significant differences between normal bone 
marrow and CML chronic phase, and between empty vector 
transfected cells and BCR-ABL ones, suggesting that IκBα 
mRNA levels are not regulated by BCR-ABL at least at the 
steady state. We then performed a stability assay of IκBα 
protein. HEK293T cells transfected with IκBα and with Bcr-
Abl were incubated for 6 hours with the proteasome inhibitor 
MG-132. BCR-ABL appeared to regulate IκBα protein 
stability at a post-translational level (Figure 2E).
IκBα is mostly studied for its inhibitory activity 
toward NF-κB, through the interaction with the NF-κB 
subunit p65 [21, 22]. IκBα is a shuttling protein that moves 
into the nucleus, where it binds to active NF-κB and inhibits 
its transcriptional activity by removing it from the nucleus. 
NF-κB was extensively studied in the pathogenesis of CML 
[23–29]. IκBα was also shown to bind to p53, which shares 
with p65 NF-κB a similar tridimensional structure [30–32]. 
TP53 is a tumor suppressor that is involved in several cellular 
processes, like senescence, cell cycle inhibition, apoptosis 
and DNA damage repair [33, 34]. In CML, p53 was shown 
to be involved in the progression into the blast crisis, where 
almost 20% of the patients display mutated TP53, while TP53 
was never found mutated/deleted in the chronic phase of the 
disease [35]. Therefore, we hypothesized that IκBα could 
also promote p53 sequestration from the nucleus in CML. To 
this aim, we performed p53 immunofluorescence in primary 
CML cells. As shown in Figure 3A, p53 is retained into the 
cytosol of CML cells. Notably, nuclear excluded p53 was 
found to co-localize with IκBα in the cytoplasm (Figure 3B). 
To better validate these observations, we confirmed that IκBα 
co-immunoprecipitates with p53 in the presence of BCR-
ABL both in transfected cells and in primary CML bone 
marrow cells (Figure 3C).
All together these data indicate that BCR-ABL 
promotes cytoplasmic sequestration of the IκBα-p53 
complex. Previous works have clearly demonstrated that 
the IκBα-p53 complex is associated with the inhibition 
of p53 [30–32]. Notably, TNFα and the tyrosine kinase 
inhibitor staurosporine were shown to disrupt this 
complex, although the mechanism was unknown [30]. 
Our observations in primary CML samples and cell lines 
suggest that BCR-ABL promotes the sequestration and 
inactivation of p53 in the cytoplasm through the interaction 
with IκBα. The inactivation of p53 through sequestration 
and/or delocalization in the cytoplasm could harbor 
important therapeutic options. To test this hypothesis, we 
treated Ba/F3 p210 BCR-ABL cells with imatinib and 
we assessed the cellular compartmentalization of p53. 
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Figure 1: IκBα in BCR-ABL positive cells. A. Representative immunohistochemistry using an anti-IκBα antibody performed on 
paraffin-embedded bone marrow from a representative CML or normal bone marrow. IHC was performed on 4 CML chronic phase samples 
with comparable results. B. Representative immunofluorescence on normal and CML primary bone marrow cells were performed to detect 
endogenous IκBα (green signal). Nuclei were stained with propidium iodide (red). Immunofluorescence was performed on 20 chronic 
phase CML samples and 3 normal bone marrow samples with comparable results. C. HeLa cells were transfected with BCR-ABL and 
IκBα plasmids. Immunofluorescence staining of IκBα (green) and BCR-ABL (red) was performed to detect IκBα localization. Nuclei were 
stained with DAPI. D. Immunofluorescence on the BV173 and K562 CML cell lines and on parental Ba/F3 and Ba/F3 p210 BCR-ABL 
cells was performed to detect IκBα (green signal). Nuclei were stained with propidium iodide (red). When indicated, cells were treated for 
6 hours with 10 μM of imatinib.
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Figure 2: IκBα interactions and phosphorylation in BCR-ABL transfected cells. A. HEK293T cells were transfected with 
the indicated plasmids and assessed by immunoprecipitation with myc-tag antibody (IκBα) and western blot. B. BV173 lysates were 
immunoprecipitated with IκBα antibody and western blot C. In vitro kinase assay with purified ABL and IκBα proteins was performed. 
P-Tyr: phospho-tyrosine. D. qRT-PCR analysis of NFKBIA (IκBα) performed on normal and CML bone marrow samples and on HEK293T 
BCR-ABL and empty vector transfected cells. E. BCR-ABL and IκBα-transfected HEK293T cells were incubated for 6 hours with 1 μM of 
MG132. Western blot analysis was performed to evaluate IκBα protein level. Tubulin was used as loading control.
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Figure 3: p53 in BCR-ABL positive cells. A. Representative immunofluorescence on normal and CML primary bone marrow cells were 
performed to detect endogenous p53 (green signal). Nuclei were stained with propidium iodide (red). Immunofluorescence was performed on 20 
chronic phase CML samples and 3 normal bone marrow samples with comparable results. B. Primary CML samples were stained with anti-IκBα 
(green) and anti-p53 (red) antibodies to assess co-localization of p53 with IkBα. C. Immunoprecipitations with IκBα antibody were performed 
on HEK293T transfected cells and on primary BM cells. D. Immunofluorescence on Ba/F3 parental and Ba/F3 p210 BCR-ABL cell line was 
performed to detect p53 (green signal). Nuclei were stained with propidium iodide (red). Right panel: Western blot on Ba/F3 p210 BCR-ABL 
imatinib-treated cells. When indicated, cells were treated with imatinib for 6 hours at a concentration of 10 μM. E. qRT-PCR analysis of p21 
performed on normal and CML bone marrow at the diagnosis (**p < 0.05) and after 3-months of imatinib treatment (***p < 0.005).
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Figure 4: Model of BCR-ABL-IκBα-p53 network in normal (upper panel) and BCR-ABL positive cells (bottom 
panel). In normal cells IκBα can shuttle from the cytoplasm to the nucleus to remove NF-κB and p53 from the DNA. In BCR-ABL positive 
cells, IκBα is mostly cytoplasmic, interacts with BCR-ABL and with p53. The BCR-ABL/IkBα network enables p53 to translocate into the 
nucleus and therefore functionally inactivate its tumor suppressive functions.
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Importantly, imatinib promotes p53 relocalization into the 
nucleus (Figure 3D) and apoptosis/growth arrest induction 
(data not shown).
To better evaluate whether the delocalization 
of p53 is associated with impairment of its function, 
we measured p21 mRNA expression in CML samples. 
TP53 is indeed known to regulate p21 expression [36]. 
As shown in Figure 3E, p21 mRNA levels are markedly 
reduced in CML primary cells, compared to normal bone 
marrow while imatinib treatment promotes p21 levels 
restoration.
In summary, we have demonstrated that in Chronic 
Myeloid Leukemia BCR-ABL physically interacts 
with IκBα, promotes its cytoplasmic localization, and 
favors the maintenance of the IκBα/p53 complex into 
the cytoplasm. As a consequence, BCR-ABL negatively 
regulates the pro-apoptotic and growth arrest potentials 
of p53 (Figure 4).
Our work leads to the following conclusions. 
Firstly, BCR-ABL-mediated tumorigenesis does not only 
depend on the direct activation of pathways involved 
in the regulation of cell growth and survival, but also 
on the ability of BCR-ABL to counteract pathways that 
suppress proliferation and survival. In line with these 
considerations, BCR-ABL was already shown to inactivate 
the tumor suppressors PP2A, PTEN and others [13, 15–17]. 
Here, we provide evidences that BCR-ABL/IκBα complex 
affects the tumor suppressive functions of p53.
Secondary, our work further highlights the 
relevance of the IκBα-p53 complex in cancer biology. 
This interaction has been already described although the 
mechanisms of regulation and the biological relevance 
were almost unknown [30–32]. Our data suggest that 
IκBα is able to orchestrate two essential factors in 
tumorigenesis. From one side IκBα negatively regulates 
the NF-κB subunit p65 and from the other p53. Therefore, 
we suggest that oncogenes could switch the balance of 
this interaction, favoring inactivation of p53. However, 
our data could not completely explain the mechanisms of 
IκBα-p53 formation and regulation. In a previous report, 
the IκBα-p53 complex is disrupted by treatment with 
the tyrosine kinase inhibitor straurosporine, suggesting 
that IκBα-p53 complex is regulated by tyrosine kinases. 
Imatinib is also able to promote IκBα-p53 disruption 
downstream of BCR-ABL, although we did not observe 
a direct IκBα tyrosine phosphorylation by BCR-ABL. 
We therefore speculate that other kinases, downstream of 
BCR-ABL, or BCR-ABL kinase independent pathways, 
could be involved in the formation and regulation of the 
IκBα-p53 complex.
Finally, our data imply that the BCR-ABL/IκBα/
p53 network harbors therapeutic implications. Storing 
an active and genetically wild-type tumor suppressor 
could indeed offer the chance to design therapies to 
reactivate p53 with dramatic cancer selective apoptosis 
induction.
MATERIALS AND METHODS
Cells, primary human samples and 
pharmacological treatments
HEK293T, HeLa, K562, BV173 cells were obtained 
from ATCC and cultured according to vendor. Parental Ba/
F3 and Ba/F3 p210 BCR-ABL were previously reported [19]. 
Twenty primary chronic phase CML and three normal bone 
marrow samples were collected at the San Luigi Hospital 
(Orbassano, Italy) with informed consent of patients at the 
time of diagnosis. Project was reviewed by the institutional 
Ethical Committee (code #10/2013). Cell lines were 
incubated with 10 μM Imatinib mesylate (Novartis) for 
6 hours and with 1 μM MG132 (Selleckchem) for 6 hours.
Plasmids and transfection
NFκBIA plasmid [20] was cloned into myc-
tagged pRK5 plasmid [15]. BCR-ABL vector was 
described elsewhere [15]. BCR vector was cloned in 
pcDNA3.1 plasmid. Transient transfection was performed 
with X-treme GeneHP (Roche) reagent according to 
manufacturer’s protocol.
Western immunoblot and immunoprecipitation
Proteins were extracted with a buffer containing 150 
mM NaCl, 1 mM EDTA, 50 mM HEPES (pH 7.5), 1% 
Triton X-100 and 10% glycerol. For immuno precipitations, 
lysates were precleared with normal mouse IgG antibody 
(Santa Cruz, #2025) or normal rabbit IgG (Santa Cruz, 
#2027)and Protein A/G-PLUS-Agarose (Santa Cruz, 
# sc-2002) for 1 hour. Then lysates were incubated with 
antibody overnight at 4°C on a rotator. Protein A/G-PLUS-
Agarose beads were added and incubated for 2 hours at 4°C 
with rotation. Agarose beads bound with immunoreactive 
complexes were washed four times with cold co-IP buffer. 
Following the final wash, immunoprecipitated complexes 
were eluted with 30 μl of 2x sample buffer, boiled for 5 min 
and analyzed using SDS-PAGE. Equal amounts of proteins 
were denatured in Laemmli sample buffer at 95°C for 
5 min, resolved by SDS–PAGE on 8% gels and 
subsequently transferred to a nitrocellulose membrane. 
Immunoblotting was carried out using antibodies against 
IκBα (Cell signaling #4814), myc-tag (Cell signaling 
#2276), p53 (Santa Cruz sc-98), Bcr (Cell signaling #3902), 
P-Tyr (Santa Cruz sc-7020), c-Abl (Cell signaling #2862). 
Blots were scanned into the ChemiDoc XRS+ system 
(Biorad) and image acquisition and analysis was performed 
using ImageLab software (Biorad).
Kinase assay
An in vitro kinase assay with purified full length 
ABL (Invitrogen, #P3049) and IκBα (BIOMOL, UW9975) 
proteins was performed as previously described [15].
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Immunofluorescence and immunohistochemistry
Immunofluorescence was performed by fixing 
cells with 4% PFA, permeabilizing them with 0.5% 
Triton X-100 and blocking with bovine serum albumin 
for 30 minutes. After blocking, cells were incubated 
with antibody at 1:100 at room temperature for 2 hours, 
followed by incubation with 1:500 secondary antibodies 
Alexa fluor-488 (Invitrogen # A-11078) and Alexa 
fluor-543 (Invitrogen # A-11030) at room temperature 
for 1 hour. Nuclei were stained with propidium iodide or 
DAPI for 5 minutes. Immunohistochemistry experiments 
were performed on formalin-fixed, paraffin-embedded 
tissues using anti-IκBα antibody (Cell Signaling, #4814) 
according to manufacturer’s protocols.
Real-time quantitative polymerase chain 
reaction
Total RNA was extracted using standard procedures. 
Quantitative Real-Time PCR (qRT-PCR) reactions and 
fluorescence measurements were performed using the 
7300 RealTime PCR System (Applied Biosystem). For 
NFKBIA and p21 quantification, specific assays with on-
demand primer/probe kits (assay ID 00355671_g1 for 
NFKBIA, Hs00355782_m1 for p21 and Hs00245445_m1 
for ABL1) (Applied Biosystems, Foster City, CA, 
USA) were conducted according to the manufacturer’s 
instructions. The NFKBIA and p21 Ct obtained by qRT-
PCR was normalized with respect to the Ct of ABL and 
expressed as 2−ΔΔCt. Universal Human Reference RNA 
(Stratagene, #740000) was used to calibrate the assay.
Statistical analysis
Statistical analysis was performed with GraphPad 
Prism v5.0d (GraphPad Software), using the Student t test. 
Significance was set at P < 0.05.
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